tiprankstipranks
Advertisement
Advertisement

IRON Stock Latest News

Disc Medicine presents updated data from RALLY-MF trial at ASCO
The FlyDisc Medicine presents updated data from RALLY-MF trial at ASCO
14h ago
IRON
Disc Medicine price target raised to $80 from $75 at Morgan Stanley
PremiumThe Fly
Disc Medicine price target raised to $80 from $75 at Morgan Stanley
19d ago
IRON
Disc Medicine reports Q1 EPS ($1.65), consensus ($1.73)
PremiumThe Fly
Disc Medicine reports Q1 EPS ($1.65), consensus ($1.73)
29d ago
IRON
Disc Medicine Completes Key Phase 1b Study of DISC-0974 in CKD Anemia: What Investors Should Watch
PremiumCompany Announcements
Disc Medicine Completes Key Phase 1b Study of DISC-0974 in CKD Anemia: What Investors Should Watch
1M ago
IRON
3 Best Stocks to Buy Today, 3/30/2026, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Today, 3/30/2026, According to Top Analysts
2M ago
IRD
GENI
Disc Medicine completes enrollment in APOLLO trial
PremiumThe FlyDisc Medicine completes enrollment in APOLLO trial
2M ago
IRON
FDA review process for accelerated approval narrows, less predictable, WSJ says
Premium
The Fly
FDA review process for accelerated approval narrows, less predictable, WSJ says
3M ago
CAPR
IRON
Disc Medicine price target raised to $79 from $78 at Wells Fargo
Premium
The Fly
Disc Medicine price target raised to $79 from $78 at Wells Fargo
3M ago
IRON
Disc Medicine Implements Restructuring Following FDA Response
PremiumCompany Announcements
Disc Medicine Implements Restructuring Following FDA Response
3M ago
8K
IRON
Disc Medicine price target lowered to $83 from $114 at Truist
PremiumThe Fly
Disc Medicine price target lowered to $83 from $114 at Truist
3M ago
IRON
Disc Medicine price target raised to $111 from $110 at Stifel
PremiumThe Fly
Disc Medicine price target raised to $111 from $110 at Stifel
3M ago
IRON
Disc Medicine: Bitopertin’s De-Risked Path to Approval Supports Buy Rating
PremiumRatings
Disc Medicine: Bitopertin’s De-Risked Path to Approval Supports Buy Rating
3M ago
IRON
Disc Medicine: Strong Cash Runway and Bitopertin Upside Support Buy Rating Despite Regulatory Setbacks
PremiumRatingsDisc Medicine: Strong Cash Runway and Bitopertin Upside Support Buy Rating Despite Regulatory Setbacks
3M ago
IRON
Disc Medicine reports FY25 EPS ($6.01) vs ($3.96) last year
Premium
The Fly
Disc Medicine reports FY25 EPS ($6.01) vs ($3.96) last year
3M ago
IRON
Disc Medicine’s RALLY-IBD Trial Puts a Spotlight on Anemia Relief in IBD Patients
Premium
Company Announcements
Disc Medicine’s RALLY-IBD Trial Puts a Spotlight on Anemia Relief in IBD Patients
3M ago
IRON
Disc Medicine price target lowered to $88 from $110 at Wedbush
PremiumThe Fly
Disc Medicine price target lowered to $88 from $110 at Wedbush
4M ago
IRON
Disc Medicine price target lowered to $125 from $153 at Cantor Fitzgerald
PremiumThe Fly
Disc Medicine price target lowered to $125 from $153 at Cantor Fitzgerald
4M ago
IRON
Disc Medicine price target lowered to $75 from $120 at Morgan Stanley
PremiumThe Fly
Disc Medicine price target lowered to $75 from $120 at Morgan Stanley
4M ago
IRON
Disc Medicine price target lowered to $110 from $125 at Stifel
PremiumThe Fly
Disc Medicine price target lowered to $110 from $125 at Stifel
4M ago
IRON
Disc Medicine price target lowered to $100 from $120 at BMO Capital
PremiumThe FlyDisc Medicine price target lowered to $100 from $120 at BMO Capital
4M ago
IRON
Disc Medicine Addresses FDA Rejection of Bitopertin Filing
Premium
Company Announcements
Disc Medicine Addresses FDA Rejection of Bitopertin Filing
4M ago
8K
IRON
Disc Medicine: Long‑Term Value Intact as Bitopertin Shifts to Lower‑Risk Traditional Approval Path
Premium
Ratings
Disc Medicine: Long‑Term Value Intact as Bitopertin Shifts to Lower‑Risk Traditional Approval Path
4M ago
IRON

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >